Oncopro Liquid Biopsy Test
Short Name: Oncopro Liquid Biopsy
Also known as: Liquid Biopsy Panel, ctDNA Mutation Panel, Circulating Tumor DNA Test, Oncopro ctDNA Panel, OncoPro 73-Gene Liquid Biopsy
Oncopro Liquid Biopsy Test test available at DNA Labs India for ₹193,050. Uses Next Generation Sequencing (NGS) on Whole Blood samples. Results in Results are typically available within 35 working days from sample receipt at the laboratory. Reports are delivered via Online Portal, Email, and WhatsApp.. Free home collection in 300+ cities across India.
🩺 Medically Reviewed By
Dr Pasupathy Arumugam
Consultant Pathologist · Reg: 21521
Last reviewed: September 7, 2026
Overview
The Oncopro Liquid Biopsy Test is performed to detect somatic mutations in 73 cancer-associated genes using circulating tumor DNA (ctDNA) from a blood sample. Its primary purposes include identifying actionable genomic alterations to guide personalized cancer treatment, expanding targeted therapy options, monitoring treatment response over time, detecting emerging resistance mutations during therapy, and assessing Microsatellite Instability (MSI) status which may indicate eligibility for immunotherapy. The test is valuable when tissue biopsy is not feasible, for longitudinal monitoring of disease progression or regression, and for identifying molecular changes that may not be captured through a single tissue biopsy due to tumor heterogeneity.
- Test Code
- 1380
- Price
- ₹193,050
- Sample Type
- Whole Blood
- Result Time
- Results are typically available within 35 working days from sample receipt at the laboratory. Reports are delivered via Online Portal, Email, and WhatsApp.
- Fasting Required
- No
- Method
- Next Generation Sequencing (NGS)
Sample Collection
Ensure the mandatory OncoPro Liquid Biopsy Clinical Information Form (Form 32) is completely and accurately filled out by the referring oncologist. This form is required and must accompany the sample. No fasting is required prior to sample collection. Inform your doctor about any ongoing cancer treatments, recent surgeries, or medications, as these may affect test results. The sample must reach the laboratory by 9:00 AM on the day of collection.
Method: Venipuncture
Laboratory Analysis
A trained phlebotomist will draw approximately 20 mL of blood from a vein in your arm using standard venipuncture. The blood will be collected into 2 Streck BCT (Blood Collection Tubes) to preserve circulating cell-free DNA integrity. The process is similar to a routine blood draw and typically takes 5 to 10 minutes.
Report Delivery
Apply gentle pressure to the puncture site with a cotton ball or gauze. Mild bruising may occur at the draw site and typically resolves within a few days. The collected sample must be shipped immediately to the laboratory at 18-22°C. Do NOT refrigerate or freeze the sample. Results will be available in approximately 35 working days from the date of sample receipt at the laboratory.
Timeline: Results are typically available within 35 working days from sample receipt at the laboratory. Reports are delivered via Online Portal, Email, and WhatsApp.
Patient Instructions
About This Test
Who Should Get This Test
The Oncopro Liquid Biopsy Test is performed to detect somatic mutations in 73 cancer-associated genes using circulating tumor DNA (ctDNA) from a blood sample. Its primary purposes include identifying actionable genomic alterations to guide personalized cancer treatment, expanding targeted therapy options, monitoring treatment response over time, detecting emerging resistance mutations during therapy, and assessing Microsatellite Instability (MSI) status which may indicate eligibility for immunotherapy. The test is valuable when tissue biopsy is not feasible, for longitudinal monitoring of disease progression or regression, and for identifying molecular changes that may not be captured through a single tissue biopsy due to tumor heterogeneity.
How to Prepare
- Collect 20 mL whole blood in 2 Streck BCT tubes (available from LPL)
- Ship the sample immediately at 18-22°C (room temperature)
- DO NOT refrigerate or freeze the sample at any point
- Duly filled OncoPro Liquid Biopsy Clinical Information Form (Form 32) is mandatory and must accompany the sample
- Sample should reach the laboratory daily by 9:00 AM
- Label the tubes clearly with patient details, date, and time of collection
- Avoid excessive shaking or agitation of the blood tubes during transport
Doctor's Notes
Reviewed by Dr Pasupathy Arumugam — MBBS, MD (Pathology) · Reg. No. 21521
"Liquid biopsy represents a paradigm shift in oncology diagnostics. The Oncopro 73-gene panel enables non-invasive detection of actionable somatic mutations from a simple blood draw, helping oncologists personalize targeted therapy strategies, monitor treatment response, and detect emerging resistance mutations without repeated invasive tissue biopsies. This is particularly valuable when tissue biopsy is not feasible or when longitudinal monitoring is required."
Last medically reviewed: September 7, 2026
Test Parameters & Specifications
Sample Stability
- Blood not collected in Streck BCT tubes
- Sample volume less than 20 mL (less than 2 Streck tubes)
- Sample refrigerated or frozen prior to analysis
- Missing or incomplete OncoPro Liquid Biopsy Clinical Information Form (Form 32)
- Hemolyzed, clotted, or visibly degraded blood sample
- Sample received more than 72 hours after collection
- Unlabeled or mislabeled sample tubes
Understanding Your Results
No actionable ctDNA mutations were identified in the 73-gene panel. This may indicate absence of detectable circulating tumor DNA, early-stage disease with insufficient ctDNA shedding, or a tumor type with low ctDNA release. Clinical correlation and repeat testing may be considered.
May not rule out cancer; consider additional diagnostic workup based on clinical suspicion.
One or more somatic mutations were identified in the analyzed genes. The report will specify the exact mutations, their variant allele frequency, and associated therapeutic implications including FDA-approved targeted therapies and relevant clinical trials.
Results may guide selection of targeted therapy, immunotherapy, or enrollment in mutation-specific clinical trials.
Microsatellite Instability High status was detected, indicating deficiency in the DNA mismatch repair system. This biomarker is associated with response to immune checkpoint inhibitor therapy (e.g., pembrolizumab).
May indicate eligibility for immunotherapy regardless of cancer type (tissue-agnostic approval).
Gene amplifications or deletions were identified in one or more of the analyzed genes. CNVs such as ERBB2 (HER2) amplification or MET amplification may have direct therapeutic implications.
May guide use of targeted therapies such as anti-HER2 agents or MET inhibitors.
Insertion or deletion mutations were identified in one or more genes. These include clinically significant alterations such as EGFR exon 19 deletions, FLT3 internal tandem duplications (ITD), and others.
May indicate sensitivity or resistance to specific targeted therapies.
Consult your oncologist or treating physician when: (1) any somatic mutations are detected in the report to discuss targeted therapy options; (2) MSI-High status is identified to evaluate immunotherapy eligibility; (3) no mutations are detected but clinical suspicion for cancer remains high; (4) to discuss whether repeat testing is appropriate; (5) to evaluate clinical trial eligibility based on mutation findings; (6) if you experience any new or worsening symptoms such as unexplained weight loss, persistent pain, fatigue, difficulty swallowing, changes in skin or moles, persistent cough, or hoarseness.
Limitations
- ⚠Detection of ctDNA depends on tumor type, stage, metabolic activity, and shedding rate into the bloodstream
- ⚠May not detect all mutations present in the primary tumor due to variable ctDNA shedding
- ⚠Cannot determine the anatomical location or histological type of the primary tumor
- ⚠False negatives are possible, particularly in low-burden or low-shedding tumors
- ⚠This test is designed for detection of somatic mutations in ctDNA and is not a replacement for comprehensive tissue-based pathology
- ⚠Results should always be interpreted in conjunction with clinical findings, imaging, and other diagnostic information by a qualified oncologist
Risks & Considerations
- ●Minor bruising or discomfort at the blood draw site
- ●Temporary lightheadedness or dizziness during or after venipuncture
- ●Rare: minor infection at the puncture site
- ●Very rare: fainting during blood collection
- ●Possible false-negative results if tumor ctDNA levels are below the detection threshold
Interfering Factors
- ●Very early-stage cancers with low tumor burden may not release sufficient ctDNA into the bloodstream for detection
- ●Recent chemotherapy or radiation treatment may transiently affect ctDNA levels and mutation detectability
- ●Hemolyzed blood samples may compromise the quality of cell-free DNA extraction
- ●Certain benign conditions may contribute background cell-free DNA, potentially affecting specificity
- ●Improper sample handling, refrigeration, or freezing of Streck tubes may degrade ctDNA
- ●Recent major surgery or trauma may release non-tumor cell-free DNA into circulation
Compare With Similar Tests
| Test | Oncopro Liquid Biopsy Test | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| Comparison | Oncopro Liquid Biopsy Test |
Frequently Asked Questions
What is the Oncopro Liquid Biopsy Test?
How much does the Oncopro Liquid Biopsy Test cost in India?
How is the Oncopro Liquid Biopsy Test performed?
What type of sample is required for this test?
How long does it take to get the results of the Oncopro Liquid Biopsy Test?
Is the Oncopro Liquid Biopsy Test painful or does it have any side effects?
Who should consider taking the Oncopro Liquid Biopsy Test?
What genes are included in the 73-gene panel?
Can the Oncopro Liquid Biopsy Test replace a traditional tissue biopsy?
Do I need to fast before the Oncopro Liquid Biopsy Test?
Is home sample collection available for the Oncopro Liquid Biopsy Test?
Can the Oncopro Liquid Biopsy Test be used to monitor cancer treatment progress?
Related Tests
B-Cell Rearrangement Detection Test
₹22,000Acute Lymphoblastic Leukemia (ALL) Cytogenetics Panel Test
₹20,000Epstein-Barr Virus Early RNA (EBER-ISH) In-Situ-Hybridization Test
₹6,000OncoPro NCCN Lung Cancer Panel with PD-L1 Test
₹140,400Acute Myeloid Leukemia (AML) Cytogenetics Panel Test
₹23,000AML ETO t(8;21) Gene Rearrangement PCR Qualitative Test
₹6,000Reference Laboratory Services
We serve as a reference laboratory for hospitals and clinics across India. Send samples from your facility with same-day pickup, priority processing, and results delivered through our online portal. Competitive institutional pricing available.
Your Data Privacy
Your medical data is protected under Indian law.
✓ Stored in India: All patient records are stored on servers located in India. No data is transferred outside the country.
✓ DPDP Act Compliant: Under the Digital Personal Data Protection Act 2023, you can request deletion of your records at any time by contacting support.
Book Your Test
Enter your details and we'll connect you within 15 minutes.